Influence of anatomic features on the effectiveness of enamel matrix derivative proteins in the treatment of proximal Class II furcation involvements.
OBJECTIVE
To evaluate the influence of furcation anatomy and bone defect morphology on the treatment of Class II proximal furcations treated with enamel matrix derivative (EMD) proteins.


METHODS
Eighteen Class II proximal furcations were treated with open-flap debridement + 24% EDTA conditioning + EMD proteins. Probing depth, gingival margin position, relative vertical and horizontal clinical attachment level, and vertical and horizontal bone levels were evaluated immediately before and 6 months after the surgeries. The changes in these parameters were correlated with vertical defect depth, number of walls, depth defect, interdental distance, root divergence, furcation distance, horizontal measure, root trunk, and furcation height, using the Pearson and Spearman rank correlation tests (a = 5%).


RESULTS
The depth defect correlated with gingival margin position (r = 0.52; P = .03), probing depth (r = 0.63; P = .005), and horizontal bone level (r = -0.46; P = .05). The furcation height also correlated with gingival margin position (r = 0.53; P = .02) and horizontal bone level (r = -0.57; P = .01). Moreover, the number of walls of vertical defect positively influenced relative vertical clinical attachment level (r = 0.47; P = .05).


CONCLUSIONS
Within the limits of this study, furcation anatomy and defect morphology influence the clinical response of EMD protein therapy in Class II proximal furcation involvements.
Department of Prosthodontics and Periodontics, Division of Periodontics, School of Dentistry at Piracicaba, State University of Campinas, Piracicaba, São Paulo, Brazil.
Renato Corrêa Viana
RC
Casarin
Erica Del Peloso
Edel P
Ribeiro
Fernanda Vieira
FV
Ribeiro
Francisco Humberto
FH
Nociti
Antonio Wilson
AW
Sallum
Enilson Antonio
EA
Sallum
Marcio Zaffalon
MZ
Casati
D000134:Acid Etching, Dental / Q000379:methods; D000328:Adult; D016301:Alveolar Bone Loss / Q000473:pathology / Q000601:surgery; D002614:Chelating Agents / Q000627:therapeutic use; D055113:Chronic Periodontitis / Q000473:pathology / Q000601:surgery; D003646:Debridement; D003746:Dental Enamel Proteins / Q000627:therapeutic use*; D004492:Edetic Acid / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D017823:Furcation Defects / Q000145:classification* / Q000473:pathology / Q000601:surgery; D005881:Gingiva / Q000473:pathology; D016557:Guided Tissue Regeneration, Periodontal / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008963:Molar / Q000473:pathology; D017622:Periodontal Attachment Loss / Q000473:pathology / Q000601:surgery; D010514:Periodontal Pocket / Q000473:pathology / Q000601:surgery; D011446:Prospective Studies; D013524:Surgical Flaps; D014092:Tooth Root / Q000473:pathology; D016896:Treatment Outcome
D002614:Chelating Agents; D003746:Dental Enamel Proteins; C109069:enamel matrix proteins; D004492:Edetic Acid